0.2606USD+0.23%Mkt Cap: 11.52M USDP/E: —Last update: 2026-06-01
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and in…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap11.52M USD
Enterprise Value13.79M USD
Revenue (TTM)21.80K USD
Gross Profit17.57K USD
Net Income (TTM)-8.64M USD
Revenue/Share0.0010 USD
Last Price0.2606 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)4.27
PEG—
EV/EBITDA—
EV/Revenue632.82
P/S510.03
P/B-4.83
EPS (TTM)-0.26
EPS (Forward)0.06
52W Range
0.17203% of range3.330
52W High3.330 USD
52W Low0.1720 USD
Profitability
Gross Margin80.59%
Oper. Margin-12886.70%
EBITDA Margin0.00%
Profit Margin-39662.77%
ROE471.92%
ROA-155.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.41M USD
CapEx (TTM)—
FCF Margin-10621.16%
FCF Yield-20.09%
Net Debt1.53M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-2.90
Current Ratio0.65
Quick Ratio0.51
Book Value/Sh-0.0530 USD
Cash/Share0.1040 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.43.42M
Float16.59M
Insiders54.26%
Institutions5.34%
Short Interest
Short Ratio0.8d
Short % Float0.32%
Short % Out.0.19%
Shares Short68.14K
Short (prev mo.)126.92K
Technical
SMA 500.3589 (-27.4%)
SMA 2000.9334 (-72.1%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)11.59M
Avg Vol (10d)34.56M
Technical Indicators
RSI (14)40.6
MACD-0.0363
MACD Signal-0.0326
MACD Hist.-0.0037
BB Upper0.4246 USD
BB Middle0.3131 USD
BB Lower0.2017 USD
BB Width71.18%
ATR (14)0.0515 USD
Vol Ratio (20d)0.25x